Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Honey bee (Apis mellifera) products have been extensively utilized in traditional medicine. Bee venom (BV) is one of the major bee products with a high concentration of the small peptide melittin (MEL) and exerts bioactivity ranging from anti-microbial to anti-inflammatory and anti-cancer. This scoping review aims to sum up research articles on the bioactivity exerted by BV and MEL published in PubMed and Scopus from 2010 onwards. PRISMA guidelines were implemented to analyze the relevant literature; we ended up with 425 research articles. Bioactivity of BV and MEL was grouped as (i) anti-inflammatory (85), (ii) immunomodulatory (37), (iii) anti-microbial (179), (iv) anti-cancer (170), and (v) anti-oxidant (32). Although there is a significant body of research on the anti-cancer and anti-microbial activity of BV and MEL, their anti-oxidant, anti-inflammatory and immunomodulatory properties have received comparatively less attention. Many studies on the immunomodulatory effects of BV or MEL have focused on cancer. However, the effects on Parkinson's and Alzheimer's disease have not been extensively studied regarding the anti-inflammatory effects. Given the critical role of the immune system and inflammatory response in cancer, neurodegenerative diseases, senescence and against infections, it is paramount to further explore the immunomodulatory and anti-inflammatory potential of BV and MEL.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.